A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine
A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- NeuroVax 300ug/mL Dose for IM Injection
What it measured
Main measures
The primary endpoint is the cumulative number of new Gd+ lesions on brain MRI at Week 24, 32, 40, and 48 for each subject. All MRIs shall be evaluated in a blinded manner by the central MRI reading facility.
MRI lesions
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: 1. Subjects between 18 and 50 years of age, inclusive. Exclusion: 1. Pregnant or lactating female.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at weeks 24, 32, 40 and 48 in subjects with relapsing remitting MS.
Loading reviews and guidelines…
History
Started
Nov 2006